Goldman has recently initiated Avidity Biosciences Inc (RNA) stock to Buy rating, as announced on September 24, 2024, according to Finviz. Earlier, on August 28, 2024, Barclays had initiated the stock to Overweight, setting a price target of $63. BofA Securities also initiated Buy rating with a price target of $40. Additionally, Cantor Fitzgerald initiated Overweight rating on March 14, 2024, with a target price of $60. Evercore ISI analysts, in their report published on May 22, 2023, also raised rating and set a price target of $20 for Avidity Biosciences Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Avidity Biosciences Inc (RNA) Stock Trading Recap
On Friday, Avidity Biosciences Inc (RNA) stock saw a modest uptick, ending the day at $50.45 which represents a slight increase of $1.93 or 3.98% from the prior close of $48.52. The stock opened at $48.5 and touched a low of $47.8 during the day, reaching a high of $50.78. The volume of shares traded was 1.21 million falling short of the average volume of 1.35 million.
Sponsored
RNA Stock Performance and Moving Averages
In recent trading, Avidity Biosciences Inc (RNA) stock price has shown some volatility, fluctuating 8.26% over the last five trades and 10.51% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 121.95%, and it has gained 8.96% in the previous three months. Currently, RNA is trading at 9.43%, 13.66%, and 63.26% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, RNA, a Healthcare sector stock, is trading 1.71% below its 52-week high but remains 945.60% above its 52-week low. The Average True Range (ATR) (14 days) of 2.42 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Avidity Biosciences Inc’s Profitability and Valuation Ratios
Avidity Biosciences Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -2690.64% and a profit margin of -2381.82%, with a gross margin of 121.95%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Avidity Biosciences Inc’s market capitalization stands at $5.91 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 557.42, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 4.51, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 7.26% of Avidity Biosciences Inc (RNA)’s shares, while financial institutions hold 93.23%.
Notable insider trades include McCarthy Teresa, Chief Human Resources Officer at Avidity Biosciences Inc (RNA), who sold 25000 shares on Oct 16 ’24, at $48.52 each, totaling $1.21 million. On Oct 07 ’24, Thompson Tamar, Director, sold 30000 shares for $44.98 each, amounting to $1.35 million. Additionally, on Oct 01 ’24, Flanagan W. Michael sold 62500 shares at $47.62 each, generating $2.98 million.
